Search
Cetuximab
go.drugbank.com/drugs/DB00002ApprovedInvestigational[A228083] EGFR has been implicated in various types of cancer, as it is often overexpressed in malignant cells [A227973] and EGFR overexpression has been linked to more advanced disease and poor prognosis … [A227963] EGFR is often mutated in certain types of cancer and serves as a driver of tumorigenesis.
Corticorelin ovine triflutate
go.drugbank.com/drugs/DB09067ApprovedIf corticorelin injection results in an increase of plasma ACTH and cortisol, the patient is diagnosed with Cushing's disease. … However, if corticorelin injection does not result in an increase of plasma ACTH and cortisol, the patient is diagnosed with ectopic ACTH syndrome.
Netupitant
go.drugbank.com/drugs/DB09048ApprovedInvestigationalNetupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy
Synonyms: 2-[3,5-Bis(trifluoromethyl)phenyl]-N,2-dimethyl-N-[4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl]propanamideEndostatin
go.drugbank.com/drugs/DB06423InvestigationalCategories: Compounds used in a research, industrial, or household settingTasonermin
go.drugbank.com/drugs/DB11626ApprovedIt was approved for use by the European Medicines Agency in April of 1999 for use as an adjunt to surgery for the subsequent removal of the tumor and in palliative care for irresectable soft tissue sarcoma
Vinorelbine
go.drugbank.com/drugs/DB00361ApprovedInvestigationalA study was done on the clearance rate of vinorelbine on individuals with various single polymorphonuclear mutations. … It was initially approved in the USA in 1990's for the treatment of NSCLC [L2010]. It is a third-generation vinca alkaloid.
Cabotegravir
go.drugbank.com/drugs/DB11751ApprovedInvestigational[A227668,L31193] Cabotegravir was granted FDA approval on 21 January 2021 in combination with rilpivirine to treat HIV-1 infection in virologically suppressed individuals. … [L31198] While previously administered once monthly only, this combination product was granted FDA approval for dosing every two months on February 01, 2022 [L40084] and without the need for an oral lead-in
Rescinnamine
go.drugbank.com/drugs/DB01180ApprovedRescinnamine is an angiotensin-converting enzyme inhibitor used as an antihypertensive drug. It is an alkaloid obtained from _Rauwolfia serpentina_ and other species of _Rauwolfia_.
Categories: Agents Acting on the Renin-Angiotensin SystemSynonyms: Trimethoxy cinnamoyl reserpate de methyl